Tuesday, November 06, 2007

In the Pipeline: FDA Advisory Committee Reviews - June 2007

The US Food and Drug Disposal (FDA) convenes body advisory administrative body meetings to destination issues in new drug applications (NDAs), biologics legal instrument applications (BLAs), or clinical trials that are currently under FDA assessment.
Although FDA advisory committees provide non-binding recommendations to the FDA, the FDA usually follows their recommendations.
The In the Comment editorial provides a summary of recently convened FDA advisory commission meetings.
At insistence time these products may have not received a match resolution from the FDA on the issues summarized in this pillar.
In June 2004, FDA advisory commission meetings convened to inspection the people topics currently under FDA exercise:Arthritis Agents Oxyprim (oxypurinol)
Arcoxia (etoricoxib)Pediatric TherapiesCongenital neonatal termination complex from influence in utero to selective serotonin reuptake inhibitors (SSRIs) and pediatric eye malformations related to antidepressants.
This is a part of article In the Pipeline: FDA Advisory Committee Reviews - June 2007 Taken from "Generic Arcoxia (Etoricoxib)" Information Blog

No comments: